Research & Regulatory News

Orforglipron (Foundayo): The MHRA Approval, Explained

UKPWritten and published by UK Peptides3 min readUpdated 5 cited sources

The short answer

On 10 August 2026 the MHRA authorised orforglipron, marketed as Foundayo by Eli Lilly, making the United Kingdom the first country in Europe to license the tablet. It is a once-daily oral GLP-1 receptor agonist approved for weight management and for glycaemic control in type 2 diabetes. It is not yet available on the NHS.

Key facts

Authorised
10 August 2026 (MHRA)
Brand name
Foundayo
Developer
Eli Lilly and Company
Class
Oral small-molecule GLP-1 receptor agonist
Administration
Once-daily tablet, no food or water restrictions
First in Europe
Yes (no EU regulator had authorised it at the time)
NHS status
Not available; NICE guidance now expected on 27 January 2027

What exactly was approved?

The MHRA granted marketing authorisation for orforglipron under the brand name Foundayo on 10 August 2026. The authorisation covers two distinct populations. The first is weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 where at least one weight-related comorbidity is present, used alongside a reduced-calorie diet and increased physical activity. The second is improving glycaemic control in adults with insufficiently controlled type 2 diabetes.

Why the approval was treated as significant

Two features made this a widely covered decision rather than a routine authorisation. The UK moved ahead of the European Medicines Agency, which is unusual for a product of this profile and was framed by the MHRA as a deliberate regulatory position. Beyond that, orforglipron is taken as an ordinary tablet at any time of day, with no fasting window and no requirement to take it with a set volume of water, a practical difference from the oral peptide products that preceded it.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the Phase 3 data showed

The pivotal obesity data were published in the New England Journal of Medicine on 16 September 2025. Over 72 weeks, mean weight reduction was 7.5% on 6 mg, 8.4% on 12 mg and 11.2% on 36 mg, against 2.1% on placebo. A separate study, ACHIEVE-3, reported in February 2026 that orforglipron produced greater weight reduction than oral semaglutide in adults with insufficiently controlled type 2 diabetes.

How it compares with the injectable incretins

It does not match them on magnitude, and the trial data do not claim to. The headline reductions from tirzepatide and from retatrutide's Phase 3 programme are substantially larger. Orforglipron's case rests on route of administration rather than effect size: an oral tablet with no absorption enhancer and no dosing ritual addresses a different problem from the one a weekly injection solves.

Reported adverse effects

The adverse-effect profile is recognisably that of the GLP-1 class and is dominated by gastrointestinal events: nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain were the most commonly reported. This is consistent with the mechanism rather than a surprise finding.

Availability in the UK

Authorisation is not the same as NHS funding. Foundayo is licensed but is not currently available through the NHS; that decision follows a separate appraisal by the National Institute for Health and Care Excellence. NICE first expected to publish its guidance on 18 November 2026; it now expects to on 27 January 2027 (NICE, checked 21 November 2026). Until the NHS funds it, access in the UK is through private prescription.

Quick reference

Orforglipron (Foundayo)Retatrutide
Molecule typeNon-peptide small molecule39-residue peptide
ReceptorsGLP-1 onlyGIP / GLP-1 / glucagon
RouteOral tablet, once dailySubcutaneous, once weekly (trials)
UK statusAuthorised 10 Aug 2026Investigational (not authorised)
Available on NHSNo (NICE guidance pending)No

Frequently asked questions

Is orforglipron a peptide?

No. It is a small molecule with no peptide bonds. That is the single most important technical fact about it and the reason it survives the stomach without an absorption enhancer.

Can I get Foundayo on the NHS?

Not at the time of writing. It holds a UK marketing authorisation, and NHS funding depends on NICE, whose guidance is now expected on 27 January 2027 (it was first due on 18 November 2026).

Does this approval change retatrutide's status?

No. Retatrutide remains investigational and is not authorised by the MHRA, EMA or FDA. The two compounds are at completely different regulatory stages.

Is orforglipron the first oral GLP-1?

It is not the first oral GLP-1 medicine (oral semaglutide preceded it) but it is the first oral GLP-1 agonist that is not a peptide, and the first authorised in Europe without food and water restrictions.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.